China 
Africa 
Explore chapters and articles related to this topic
Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine
Published in Shaker A. Mousa, Raj Bawa, Gerald F. Audette, The Road from Nanomedicine to Precision Medicine, 2020
Tetsuya Fujimura, Kenichi Takayama, Satoru Takahashi, Satoshi Inoue
Systematic treatment for advanced or metastatic PC includes androgen deprivation therapy (ADT) or chemotherapy. Conventional ADT involved surgical or medical castration and the administration of anti-androgen agents, such as bicalutamide, flutamide, and nilutamide. Recently, new anti-androgen agents, such as enzalutamide and abiraterone, have been approved for castration-resistant PC (CRPC) [2]. Docetaxel and cabazitaxel are also available for CRPC. However, effects of these new agents are transitory. Moreover, they are relatively expensive, costing $10,759 for 160 mg of enzalutamide; $9817 for 1000 mg of abiraterone per month; $1919 for 120 mg of docetaxel; and $10,639 for 40 mg of cabazitaxel, respectively (https://www.drugs.com/price-guide/). To improve cancer-specific survival (CSS) and reduce the cost incurred on drugs used for advanced PC treatment, durable and economic therapeutic strategies are warranted worldwide. Here, we reviewed the literature pertaining to endocrine therapy and proposed a new therapeutic strategy involving estrogen and androgen signal blockade (EAB) for advanced PC.
Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine
Published in Shaker A. Mousa, Raj Bawa, Gerald F. Audette, The Road from Nanomedicine to Precision Medicine, 2019
Tetsuya Fujimura, Kenichi Takayama, Satoru Takahashi, Satoshi Inoue
Systematic treatment for advanced or metastatic PC includes androgen deprivation therapy (ADT) or chemotherapy. Conventional ADT involved surgical or medical castration and the administration of anti-androgen agents, such as bicalutamide, flutamide, and nilutamide. Recently, new anti-androgen agents, such as enzalutamide and abiraterone, have been approved for castration-resistant PC (CRPC) [2]. Docetaxel and cabazitaxel are also available for CRPC. However, effects of these new agents are transitory. Moreover, they are relatively expensive, costing $10,759 for 160 mg of enzalutamide; $9817 for 1000 mg of abiraterone per month; $1919 for 120 mg of docetaxel; and $10,639 for 40 mg of cabazitaxel, respectively (https://www.drugs.com/price-guide/). To improve cancer-specific survival (CSS) and reduce the cost incurred on drugs used for advanced PC treatment, durable and economic therapeutic strategies are warranted worldwide. Here, we reviewed the literature pertaining to endocrine therapy and proposed a new therapeutic strategy involving estrogen and androgen signal blockade (EAB) for advanced PC.
MRI Imaging of Seminal Vesicle Invasion (SVI) in Prostate Adenocarcinoma
Published in Ayman El-Baz, Gyan Pareek, Jasjit S. Suri, Prostate Cancer Imaging, 2018
Samuel A. Gold, Graham R. Hale, Kareem N. Rayn, Vladimir Valera, Jonathan B. Bloom, Peter A. Pinto
In a case study presented by Somwaru et al. [85], fusion biopsy was able to successfully detect a focus of malignant ectopic prostate tissue in one seminal vesicle. Repeat 12-core sextant biopsies yielded benign prostatic tissue (including at the prostatic base), but with use of mpMRI-TRUS fusion-guided biopsy, a suspicious lesion was visualized in the left seminal vesicle and sampled to confirm Gleason 7 (4 + 3) primary PCa arising in the seminal vesicle without glandular or trans-capsular involvement. This was staged as T3b disease and the patient was treated with external beam radiation plus androgen deprivation therapy [85]. The repeated benign systematic biopsies may have merely indicated follow-up PSA testing without intervention.
Identification of potential driving genes in prostatic cancer using complex network analysis
Published in Computer Methods in Biomechanics and Biomedical Engineering: Imaging & Visualization, 2022
TaekWon Zeyuan Song, Xiao-Cong Zhen, Wensuo Gao, Wenyan Zhu
Since 2008, prostatic cancer has become the first male cancer in Department of Urology, because of the incidence rate (William et al. 2018). Androgen deprivation therapy (ADT) is the main systemic treatment for advanced prostate cancer, but most patients will inevitably enter into androgen resistance state after 2–3 years of treatment and become castrated resistant prostate cancer (CRPC) (Tannock et al. 2004; Rijnders et al. 2017). Up to now, docetaxel-based chemotherapy is often used in patients with metastatic CRPC in China (Chokkalingam et al. 2001). After chemotherapy with docetaxel, the life quality of most patients improves, and the overall survival period prolongs. Unfortunately, after a period of chemotherapy, drug resistance still occurs (Nelson et al. 2003; Tannock et al. 2004). Now, there is no definitive therapy for this cancer (Chan et al. 2020); therefore, a better understanding of the molecular mechanisms which underlies the disease pathogenesis is important.
Theranostic approaches in nuclear medicine: current status and future prospects
Published in Expert Review of Medical Devices, 2020
Luca Filippi, Agostino Chiaravalloti, Orazio Schillaci, Roberto Cianni, Oreste Bagni
Prostate cancer (PC) represents one of the most common malignancies in men and a leading cause of death due to cancer in males [50]. The first-line treatment of PC is represented by surgery, when feasible, or by ablative radiotherapy. Since PC is a hormone-dependent malignancy, androgen deprivation therapy (ADT) is widely used for treating patients with advanced disease and also for those subjects with localized disease but at high-risk of relapse. In case of PC progression in spite of ADT, the disease is defined as castration-resistant prostate cancer (CRPC) [51], which represents an aggressive status and a therapeutic challenge for physicians. The management of PC has been deeply changed by the introduction in screening of the prostate-specific antigen (PSA), which is an androgen-regulated serine protease produced by both prostate epithelial cells and prostate cancer. The routine use of PSA test in clinical practice led to an increased detection of patients at an early stage and a significant improvement in survival [52].